EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Purine Nucleoside Phosphorylase Inhibition Rebalances Purine Metabolism and Attenuates Organ Damage in Sickle Cell Mice

Adekunle Emmanuel Alagbe iD, Lynda Little-Ihrig, Stephanie M Mutchler, Edwin K Jackson, Enrico M Novelli, Stevan P Tofovic iD

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70996 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Adekunle Emmanuel Alagbe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Purine-Nucleoside Phosphorylase, Anemia, Sickle Cell, Purines, Enzyme Inhibitors. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, The Precision Medicine Institute in partnership with PittSciVelo from the University of Pittsburgh, American Society of Hematology Inclusion Pathway (HIP) Fellow Award (AEA)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Red blood cells (RBCs) contain the highest purine nucleoside phosphorylase (PNP) level per cell volume, yet the role of PNP in the pathogenesis of sickle cell disease (SCD) is incompletely understood, highlighting an important gap in our knowledge of the disease. Previously, we reported increased PNP release by RBCs and accelerated purine nucleoside metabolism with increased production of pro‐oxidant, pro‐inflammatory and vasculotoxic byproducts in children with SCD and animal models of hemolytic injury. Thus, we hypothesized that PNP inhibition would reduce hemolysis and attenuate end‐organ damage in SCD. In adult patients with SCD ( n = 63), plasma PNP levels were markedly elevated compared to controls ( n = 27; p < 0.001) and correlated positively with LDH ( r = 0.6032, p < 0.0001) and negatively with haemoglobin ( r = −0.4523, p = 0.0002). SCD mice also showed accelerated purine metabolism compared to controls. Treatment with the PNP inhibitor 8‐aminoguanosine (8‐AG) increased inosine and guanosine and reduced downstream vasculotoxic byproducts hypoxanthine ( p = 0.036), xanthine ( p = 0.004) and guanine ( p = 0.047), indicating efficient PNP inhibition. 8‐AG treatment rebalanced the purine metabolome in SCD mice to favour protective over harmful purine metabolites without negatively affecting haematological parameters. This was associated with reduced hemolysis and decreased splenomegaly, hepatomegaly, and hepatic and renal injury. This study suggests that PNP is an important erythrocytic damage‐associated molecular pattern molecule involved in the complex pathophysiology of SCD and proposes PNP inhibitors as a new therapeutic option for SCD and other hemolytic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purine-Nucleoside PhosphorylaseAnemia, Sickle CellPurinesEnzyme InhibitorsAnimalsMiceHumansMaleFemaleHemolysisAdultErythrocytesDisease Models, AnimalGuanosine

Substanzen

Purine-Nucleoside PhosphorylasePurinesEnzyme InhibitorsGuanosinepurine

Autor:innen und Institutionen

  • Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Division of Renal Electrolytes, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Division of Classical Hematology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Adekunle Emmanuel Alagbe, Stevan P Tofovic

Förderung

  • NIDDK NIH HHS
  • The Precision Medicine Institute in partnership with PittSciVelo from the University of Pittsburgh
  • American Society of Hematology Inclusion Pathway (HIP) Fellow Award (AEA).
  • Vitalant and The Hemophilia Center of Western Pennsylvania
  • P3HVB award in Hemostasis and Vascular Biology, funded by the University of Pittsburgh Vascular Medicine Institute

Zitieren

APA

Alagbe, A. E., Little-Ihrig, L., Mutchler, S. M., Jackson, E. K., Novelli, E. M., & Tofovic, S. P. (2025). Purine Nucleoside Phosphorylase Inhibition Rebalances Purine Metabolism and Attenuates Organ Damage in Sickle Cell Mice. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70996

Vancouver

Alagbe AE, Little-Ihrig L, Mutchler SM, Jackson EK, Novelli EM, Tofovic SP. Purine Nucleoside Phosphorylase Inhibition Rebalances Purine Metabolism and Attenuates Organ Damage in Sickle Cell Mice. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70996

BibTeX
@article{Alagbe2025,
  author = {Alagbe, Adekunle Emmanuel and Little-Ihrig, Lynda and Mutchler, Stephanie M and Jackson, Edwin K and Novelli, Enrico M and Tofovic, Stevan P},
  title = {Purine Nucleoside Phosphorylase Inhibition Rebalances Purine Metabolism and Attenuates Organ Damage in Sickle Cell Mice},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70996}
}
Kostenlos starten →